| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
180,310,000 |
| Market
Cap: |
41.24(B) |
| Last
Volume: |
799,597 |
Avg
Vol: |
866,609 |
| 52
Week Range: |
$191.51 - $228.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK™, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
55,541 |
496,602 |
| Total Sell Value |
$0 |
$0 |
$11,412,520 |
$89,768,813 |
| Total People Sold |
0 |
0 |
7 |
8 |
| Total Sell Transactions |
0 |
0 |
19 |
72 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Welch Daniel G |
Director |
– • – |
2021-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,402 |
41,931 |
|
- |
|
| Lippman Marc E |
Director |
– • – |
2021-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,402 |
53,740 |
|
- |
|
| Baker Julian |
Director |
– • • |
2021-05-14 |
4 |
A |
$0.00 |
$0 |
I/I |
2,804 |
43,309,073 |
|
- |
|
| Baker Julian |
Director |
– • • |
2021-05-14 |
4 |
OE |
$19.02 |
$665,700 |
I/I |
35,000 |
43,307,671 |
|
- |
|
| Simonian Nancy A |
Director |
– • – |
2021-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,402 |
27,500 |
|
- |
|
| Orwin John A |
Director |
– • – |
2021-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,402 |
27,500 |
|
- |
|
| Love Ted W |
Director |
– • – |
2021-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,402 |
3,201 |
|
- |
|
| Gryska David W |
Director |
– • – |
2021-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,402 |
46,250 |
|
- |
|
| Liu Jean I |
GC/EVP, Leg Affairs |
• – – |
2021-05-11 |
4 |
AS |
$140.00 |
$148,540 |
D/D |
(1,061) |
64,051 |
|
14% |
|
| Siegall Clay B |
President and CEO |
• • – |
2021-05-06 |
4 |
AS |
$134.29 |
$3,961,824 |
D/D |
(29,353) |
715,209 |
|
12% |
|
| Siegall Clay B |
President and CEO |
• • – |
2021-05-06 |
4 |
OE |
$15.46 |
$453,797 |
D/D |
29,353 |
722,932 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2021-04-09 |
4 |
AS |
$141.42 |
$1,788,924 |
D/D |
(12,602) |
715,209 |
|
11% |
|
| Siegall Clay B |
President and CEO |
• • – |
2021-04-09 |
4 |
OE |
$15.46 |
$194,827 |
D/D |
12,602 |
721,310 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2021-04-08 |
4 |
AS |
$144.40 |
$2,431,816 |
D/D |
(16,751) |
715,209 |
|
11% |
|
| Siegall Clay B |
President and CEO |
• • – |
2021-04-08 |
4 |
OE |
$15.46 |
$258,970 |
D/D |
16,751 |
724,376 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2021-03-04 |
4 |
AS |
$144.92 |
$4,277,764 |
D/D |
(29,353) |
715,209 |
|
-2% |
|
| Siegall Clay B |
President and CEO |
• • – |
2021-03-04 |
4 |
OE |
$15.46 |
$453,797 |
D/D |
29,353 |
726,618 |
|
- |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2021-03-02 |
4 |
AS |
$152.10 |
$1,838,623 |
D/D |
(12,000) |
129,889 |
|
-5% |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2021-03-02 |
4 |
OE |
$15.46 |
$185,520 |
D/D |
12,000 |
141,889 |
|
- |
|
| Liu Jean I |
GC/EVP, Leg Affairs |
• – – |
2021-02-17 |
4 |
OE |
$35.95 |
$200,466 |
D/D |
4,846 |
65,112 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2021-02-04 |
4 |
AS |
$163.09 |
$4,860,105 |
D/D |
(29,353) |
715,209 |
|
-9% |
|
| Siegall Clay B |
President and CEO |
• • – |
2021-02-04 |
4 |
OE |
$15.46 |
$453,797 |
D/D |
29,353 |
720,818 |
|
- |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2021-02-02 |
4 |
D |
$163.97 |
$119,370 |
D/D |
(728) |
109,544 |
|
- |
|
| Liu Jean I |
GC/EVP, Leg Affairs |
• – – |
2021-01-15 |
4 |
AS |
$180.00 |
$900,000 |
D/D |
(5,000) |
60,266 |
|
-19% |
|
| Liu Jean I |
GC/EVP, Leg Affairs |
• – – |
2021-01-15 |
4 |
OE |
$35.95 |
$179,750 |
D/D |
5,000 |
65,266 |
|
- |
|
952 Records found
|
|
Page 12 of 39 |
|
|
